Sun Pharmaceutical Industries, an international, integrated, speciality pharmaceutical company, today announced the launch of Imatinib Mesylate tablets in US market.
Earlier in December 2015, the company's subsidiary received final approval for the said tablets from United States Food and Drug Administration (USFDA) in December 2015.
As part of this launch, in addition to strengthening distribution in USA, the company has rolled-out unique Sun Pharma Imatinib Mesylate savings card program.
Imatinib Mesylate tablets are therapeutic equivalent to Gleevec for indications approved by the USFDA.
Shares of the company declined Rs 2.8, or 0.32%, to settle at Rs 870.20. The total volume of shares traded was 162,280 at the BSE (Monday).